Bharat Biotech seeks DCGI nod for booster trial of Covaxin among kids aged 2-18 years

Mangalore Today News Network

New Delhi, May 04, 2022: Bharat Biotech has written to the Drugs Controller General of India (DCGI) seeking permission to to conduct a booster trial of its Covid-19 vaccine, Covaxin, among those aged between two and 18.

 

Last month, the DCGI had granted restricted emergency use authorisation to Bharat Biotech’s Covaxin for children aged 6 to 12 years.

The panel had approved Covaxin for emergency use in children above 12 years in December 2021.

India began administering third dose or booster shots of vaccines to the healthcare and frontline workers and those aged 60 and above with comorbidities on January 10 this year.

The comorbidity clause was removed in March making all people aged above 60 eligible for the precaution dose of Covid vaccine.

Presently, booster shot of Covaxin and Covishield is administered to all those aged above 18 who have completed nine months after the second dose.

Courtesy: India Today